Core Insights - Codexis has set a revenue target of $72 million to $76 million for 2026, driven by the growth of its ECO Synthesis platform and expanding CDMO partnerships [2] Group 1: Company Strategy - CEO Alison Moore emphasized that Codexis is now concentrating on RNA medicine, having developed the ECO Synthesis manufacturing platform to tackle challenges in current siRNA production technology [2]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [21] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [21] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, up from 56% in the prior year [22] - Net income for Q4 2025 was $9.6 million, compared to a net loss of $10.4 million in Q4 2024; net loss for the full year 2025 was $44 million, improved from a loss of $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin, with stabilization in revenue, supported by a robust pipeline of drugs in late-stage clinical studies [10] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling production to 100 grams, with plans to reach half a kilo by the end of 2026 [6][7] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in five years is estimated to be $2 billion, with a growing demand for siRNA medicines at a rate of 5%-10% per year [5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [57] Company Strategy and Development Direction - The company is focused on establishing itself as a key technology provider in the RNA medicine market through its ECO Synthesis platform, which aims to address challenges in siRNA production [4][5] - Plans include scaling up production capabilities, achieving GMP certification, and expanding partnerships with CDMOs to enhance manufacturing processes [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the ECO Synthesis platform and the overall siRNA market, highlighting the importance of innovation and customer collaboration [12][28] - The company aims to demonstrate proof of success through new contracts and licensing deals in 2026, while maintaining a focus on financial performance and expense management [27][29] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value of stereoisomer control - Management is actively exploring the biological activity of stereo configurations and plans to present data at the TIDES USA meeting, with several customers interested in collaboration [31][32] Question: Understanding the recent deal process - The recent deal involved a small organization with a cardiovascular asset, highlighting the long-term discussions and mutual excitement about the ECO Synthesis platform's capabilities [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, with expectations that successful data will lead to IND submissions and larger contracts for clinical trials [41][43] Question: Revenue guidance visibility - Management indicated a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, though some estimates remain speculative at the beginning of the year [50][51] Question: Growth expectations for biocatalysis business - The small molecule biocatalysis business is expected to stabilize and continue to fuel growth, while higher growth rates are anticipated from the ECO side of the business [62][65]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [20] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [20] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, an increase from 56% in the prior year [20][21] - Net income for Q4 2025 was $9.6 million, compared to a loss of $10.4 million in Q4 2024, while the net loss for the full year 2025 was $44 million, down from $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin in 2025, with stabilization in revenue expected to fuel growth for the next 3-5 years [9] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling up production to 100 grams, with plans to reach half a kilo by the end of 2026 [5][6] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in RNA medicine is estimated to be $2 billion in five years, with a growing demand for siRNA medicines at a rate of 5%-10% per year [4][5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [55] Company Strategy and Development Direction - The company aims to establish itself as a key technology provider in the RNA medicine market, focusing on the ECO Synthesis platform to address production challenges [4][5] - Plans for 2026 include scaling up the ECO Synthesis manufacturing platform, achieving half-kilogram scale, and beginning construction of a GMP facility to support customer needs [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for siRNA therapeutics and the company's ability to meet this demand through innovative technology [55] - The company anticipates that 2026 will be a year of significant progress, with a revenue target of $72 million to $76 million, and expects to maintain stable gross margins [25][27] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value for stereoisomer control - Management is actively exploring the biological activity of stereo configurations generated by the ECO Synthesis platform and plans to present data at the TIDES USA meeting [31][32] Question: Understanding the recent announced deal - The recent deal involves a small organization with a cardiovascular asset, and discussions have been ongoing for many months to address their manufacturing challenges [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, and if successful, the company will progress to IND submissions and potentially commercial agreements for larger quantities [41][43] Question: Revenue guidance visibility - Management indicated that a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, with some speculative elements due to the early part of the year [49][50] Question: Industry demand for siRNA - Management noted that the siRNA therapeutic pipeline is vibrant, with a growing number of assets in clinical trials, projecting a significant increase in demand by 2030 [53][55] Question: Revenue mix and growth expectations - The company expects growth to primarily come from the ECO side of the business, while the small molecule biocatalysis business is expected to stabilize and contribute to growth over the next few years [60][63]

Summary of Wave Life Sciences FY Conference Call Company Overview - **Company**: Wave Life Sciences (NasdaqGM: WVE) - **Focus**: RNA medicine and oligonucleotide optimization, with a strong emphasis on human clinical genetics and innovative chemistry [2][4] Key Points from 4Q Results - **Pipeline Development**: Significant advancements in the pipeline, particularly in obesity treatment with Inhibin E and RNA editing for alpha-1 antitrypsin deficiency [3][4] - **Clinical Data**: Upcoming clinical data expected for Inhibin E, including 240 mg six-month data and 400 mg three-month data [3][15] Obesity Treatment Insights - **Targeted Mechanism**: Inhibin E aims to address obesity by reducing visceral fat without significant loss of lean muscle mass, which is crucial for metabolic health [6][10][14] - **Clinical Feedback**: Key opinion leaders (KOLs) are interested in the mechanism that focuses on body composition rather than just weight loss [5][12] - **Initial Results**: At three months, the 240 mg dose showed nearly 10% reduction in visceral fat and a 0.9% increase in lean mass, indicating a favorable profile compared to existing therapies [13][19] Future Expectations - **Data Anticipation**: The 400 mg cohort data is expected to provide insights into dose dependency and time dependency of fat loss [17][19] - **Regulatory Considerations**: The company is confident in meeting FDA requirements for obesity drugs, focusing on both weight loss and body composition improvements [45][49] RNA Editing Program - **Alpha-1 Antitrypsin Deficiency**: The program aims to correct the deficiency by producing endogenous proteins, with potential for accelerated approval based on existing data [66][75] - **Regulatory Engagement**: Discussions with regulators are ongoing to establish a clear path for market entry and confirmatory studies [75][76] Strategic Insights - **Combination Therapies**: There is potential for Inhibin E to be used in combination with GLP-1 therapies, enhancing treatment options for obesity [52][54] - **Market Potential**: The company sees a significant opportunity in addressing the obesity epidemic, with a scalable and accessible treatment model [58][60] Innovations and Future Pipeline - **Bifunctional Modality**: The company is exploring bifunctional modalities that can target multiple pathways, enhancing therapeutic efficacy [78][80] - **Targeting Multiple Cell Types**: Future developments may include targeting both adipocytes and hepatocytes, broadening the therapeutic applications in cardiometabolic diseases [80] Conclusion - Wave Life Sciences is positioned at a critical juncture with innovative approaches to RNA medicine, particularly in obesity and genetic disorders. The upcoming clinical data and regulatory discussions will be pivotal in shaping the future of its therapies and market presence.

Core Viewpoint - Stoke Therapeutics has initiated the Phase 1 OSPREY study for STK-002, targeting Autosomal Dominant Optic Atrophy (ADOA), a rare genetic condition leading to vision loss [1] Company Summary - Stoke Therapeutics is focused on restoring protein expression through RNA medicine [1] - The company has announced the dosing of the first patient in its clinical trial for STK-002 [1] Industry Summary - ADOA is characterized as a rare genetic disease that results in progressive and irreversible vision loss, typically beginning in early childhood [1]

Zorevunersen for Dravet Syndrome - Stoke Therapeutics is advancing zorevunersen as a potential disease-modifying therapy for Dravet Syndrome[9] - Phase 3 study (EMPEROR) enrollment is expected to complete in Q2 2026 with data readout in mid-2027 to support NDA[12, 38] - Approximately 330 patients have been identified globally for the EMPEROR study, with ~60 in screening and ~60 randomized[12, 39] - Data from ongoing OLE studies show continuing improvements in cognition and behavior over 36 months[24] - Zorevunersen demonstrated significant reduction in major motor seizure frequency at 6 months compared to natural history data, with an 8248% reduction compared to a 2043% reduction in the natural history group (P=00181)[26] - In OLE studies, 86% of patients experienced CSF protein elevation, classified as a TEAE in 45%[31] STK-002 for Autosomal Dominant Optic Atrophy (ADOA) - A Phase 1 study of STK-002 for ADOA has been initiated in the UK and Europe[11] Financial Status and Collaboration - Stoke Therapeutics had approximately $3917 million in cash, cash equivalents, and marketable securities as of December 31, 2025, with funding anticipated into 2028[12] - A strategic collaboration with Biogen exists for the development and commercialization of zorevunersen, with Biogen holding exclusive commercialization rights outside of the US, Canada, and Mexico[48] - The Biogen collaboration includes $165 million upfront, shared development costs, and potential milestone payments of $385 million[49] Market Opportunity - There are approximately 38,000 patients with Dravet syndrome across 7 major markets[40, 44]

Core Insights - Stoke Therapeutics and Biogen announced longer-term follow-up analyses from ongoing open-label extension studies of zorevunersen, indicating its potential as a disease-modifying medicine for Dravet syndrome [1] Company Overview - Stoke Therapeutics is a biotechnology company focused on restoring protein expression through RNA medicine [1] - Biogen Inc. is a biotechnology company that collaborates with Stoke Therapeutics on the zorevunersen studies [1] Product Development - The ongoing studies of zorevunersen are aimed at evaluating its effectiveness in treating Dravet syndrome, a severe form of epilepsy [1] - The new results from the studies support the potential of zorevunersen as a disease-modifying treatment [1]

Core Insights - Stoke Therapeutics has appointed Ian F. Smith as Chief Executive Officer, who has been serving as Interim CEO since March 2025 and has been a board member since 2023 [1][3] - The company is advancing its lead investigational medicine, zorevunersen, in a global Phase 3 study for Dravet syndrome, a severe developmental and epileptic encephalopathy [2][8] - The collaboration with Biogen Inc. for zorevunersen allows Stoke to retain exclusive rights in the U.S., Canada, and Mexico, while Biogen holds rights for the rest of the world [2] Company Leadership - Ian F. Smith is recognized for his deep experience in rare disease drug development and has a strong track record in building and leading teams [3][4] - Arthur Tzianabos, who has been on the board since 2018, will resume his role as Chairman after serving as Executive Chairman during the CEO search [1][6] Clinical Development - The pivotal Phase 3 EMPEROR study for zorevunersen has commenced, contributing to the company's growth and value creation for shareholders [3] - Stoke is also expanding its pipeline with a second clinical program targeting Autosomal Dominant Optic Atrophy [3] Company Background - Stoke Therapeutics focuses on restoring protein expression through RNA medicine, utilizing its proprietary TANGO approach to develop antisense oligonucleotides [8] - The company is headquartered in Bedford, Massachusetts, and aims to address diseases caused by a loss of approximately 50% of normal protein levels [8]

Core Insights - Zorevunersen shows potential as the first disease-modifying treatment for Dravet syndrome, with significant reductions in seizure frequency and improvements in cognitive and behavioral outcomes over three years of treatment [2][3][12] Efficacy Results - In Phase 1/2a studies, patients receiving initial doses of 70 mg of zorevunersen experienced a median seizure reduction of 84.8% and an increase of eight seizure-free days per 28 days at three months post-treatment [4] - In open-label extension studies, 94% of eligible patients continued treatment, with 77% remaining after three years, sustaining reductions in major motor seizure frequency [5] - Improvements in quality of life were noted, with an 18-point increase in EuroQol Visual Analog Scale (EQ-VAS) scores over three years [6] Safety Profile - Zorevunersen was generally well tolerated, with treatment-emergent adverse events (TEAEs) reported in 30% of patients in Phase 1/2a studies and 53% in open-label extension studies [7] - The most common TEAE was elevated cerebrospinal fluid (CSF) protein levels, occurring in 14% of patients in Phase 1/2a and 44% in open-label extension studies [7] Study Design - The Phase 1/2a studies involved 81 patients aged 2 to 18 with refractory Dravet syndrome, focusing on safety, pharmacokinetics, and seizure frequency [9] - The ongoing EMPEROR Phase 3 study aims to further evaluate zorevunersen's efficacy and safety in a larger population [13] Company Background - Biogen and Stoke Therapeutics are collaborating on the development of zorevunersen, which has received orphan drug designation and Breakthrough Therapy Designation from the FDA [12][14] - Stoke Therapeutics focuses on restoring protein expression through RNA medicine, with zorevunersen being their first investigational product [16]